Bone loss in Crohn's disease: Exercise as a potential countermeasure

Inflammatory Bowel Diseases

Volumn 11, Issue 12, 2005, Pages 1108-1118

  Lee, Naomi ^a   Radford Smith, Graham ^b   Taaffe, Dennis R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CALCIUM; CORTICOSTEROID; CYTOKINE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; STEROID; VITAMIN D;

BONE DENSITY; BONE MASS; BONE METABOLISM; CELL FUNCTION; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DIET; DISEASE EXACERBATION; EXERCISE; FRACTURE; GENETIC PREDISPOSITION; HUMAN; MALABSORPTION; NONHUMAN; NUTRITIONAL INTOLERANCE; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

BONE DENSITY; BONE DISEASES, METABOLIC; CROHN DISEASE; DIET; EXERCISE; FRACTURES, BONE; GENETIC PREDISPOSITION TO DISEASE; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 27944453906     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000192325.28168.08     Document Type: Review

References (94)

1. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4:368-381.
2. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int, 1997. 7(1): p. 1-6.
3. Sambrook PN, Seeman E, Phillips SR, et al, and Osteoporosis Australia; National Prescribing Service. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust. 2002;176(Suppl):S1-S16.
4. Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: there is a difference between CD and ulcerative colitis. J Intern Med. 2000;247:63-70.
5. Habtezion A, Silverberg MS, Parkes R, et al. Risk factors for low bone density in CD. Inflamm Bowel Dis. 2002;8:87-92.
6. Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with CD. Dig Dis Sci. 1998;43:2500-2506.
7. Dinca M, Fries W, Luisetto G, et al. Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol. 1999;94:1292-1297.
8. Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with CD but not in patients with ulcerative colitis: a population based study. Gut. 1997;40:313-319.
9. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228-233.
10. Staun M, Tjellesen L, Thale M, et al. Bone mineral content in patients with CD. A longitudinal study in patients with bowel resections. Scand J Gastroenterol. 1997;32:226-232.
11. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci. 1992;37:1396-1403.
12. Schoon EJ, van Nunen AB, Wouters RS, et al. Osteopenia and osteoporosis in CD: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl. 2000;(232):43-47.
13. Schulte C, Dignass AU, Mann K, et al. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:268-275.
14. van Staa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003;125:1591-1597.
15. Vestergaard P, Krogh K, Rejnmark L, et al. Fracture risk is increased in CD, but not in ulcerative colitis. Gut. 2000;46:176-181.
16. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac Disease, CD, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol. 2002;156:1-10.
17. Card T, West J, Hubbard R, et al. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004;53:251-255.
18. Tjellesen L, Nielsen PK, Staun M. Body composition by dual-energy X-ray absorptiometry in patients with CD. Scand J Gastroenterol. 1998;33:956-960.
19. Kanis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-1141.
20. Siffiledeen JS, Fedorak RN, Siminoski K, et al. Bones and Crohn's: risk factors associated with low bone mineral density in patients with CD. Inflamm Bowel Dis. 2004;10:220-228.
21. Haugeberg G, Vetvik K, Stallemo A, et al. Bone density reduction in patients with Crohn disease and associations with demographic and disease variables: cross-sectional data from a population-based study. Scand J Gastroenterol. 2001;36:759-765.
22. Cino M, Greenberg GR. Bone mineral density in CD: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol. 2002;97:915-921.
23. Jahnsen J, Falch JA, Mowinckel P, et al. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol. 2004;39:145-153.
24. Sylvester FA, Wyzga N, Hyams JS, et al. Effect of CD on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res. 2002;17:695-702. [the official journal of the American Society for Bone and Mineral Research]
25. Ghosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in CD, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994;107:1031-1039.
26. Franchimont NPV, Collette J, Vermeire S, et al. Rapid improvement of bone metabolism after infliximab treatment in CD. Aliment Pharmacol Ther. 2004;20:607-614.
27. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002;57:M326-M332.
28. Roubenoff R, Roubenoff RA, Cannon JG, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest. 1994;93:2379-2386.
29. Schols AM, Buurman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51:819-824.
30. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20:683-693.
31. Furuta I, Kobayashi N, Fujino T, et al. Bone mineral density of the lumbar spine is associated with TNF gene polymorphisms in early postmenopausal Japanese women. Calcif Tissue Int. 2004;74:509-515.
32. Langdahl BL, Carstens M, Stenkjaer L, et al. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res. 2002;17:1245-1255.
33. Mann V, Hobson EE, Li B, et al. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest. 2001;107:899-907.
34. Moffett SPZJ, Oakley JI, Beck TJ, et al, for the SOF Research Group. Tumour necrosis factor alpha polymorphism, bone strength phenotypes, and the risk of fracture in older women. Journal of Clinical Endocrinology and Metabolism, 2005(March 29):Epub ahead of print.
35. Spotila LD, Rodriguez H, Koch M, et al. Association of a polymorphism in the TNFR2 gene with low bone mineral density. J Bone Miner Res. 2000;15:1376-1383.
36. Tasker PN, Albagha OM, Masson CB, Reid DM, et al. Association between TNFRSF1B polymorphisms and bone mineral density, bone loss and fracture. Osteoporos Int. 2004;15:903-908.
37. van Heel DA, Udalova IA, De Silva AP, et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. Hum Mol Genet. 2002;11:1281-1289.
38. Nanes MS. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene. 2003;321:1-15.
39. Fowler EV, Eri R, Hume G, Johnstone S, et al. TNF and IL10 SNPs act together to predict disease behaviour in Crohn's disease. J Med Genet. 2005;42:523-528.
40. Nemetz A, Toth M, Garcia Gonzalez MA, et al. Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut. 2001;49:644-649.
41. Schulte C, Goebell H, Roher HD, et al. Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease. Dig Dis Sci. 2001;46:2521-2528.
42. Schulte CM, Dignass AU, Goebell H, et al. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000;119:909-920.
43. Brzezinski A. Progress in treatment for CD. Am J Gastroenterol. 2001;96:626-627.
44. de Jong DJ, Corstens FH, Mannaerts L, et al. Corticosteroid-induced osteoporosis: does it occur in patients with CD? Am J Gastroenterol. 2002;97:2011-2015.
45. Franchimont DP, Louis E, Croes F, et al. Clinical pattern of corticosteroid dependent CD. Eur J Gastroenterol Hepatol. 1998;10:821-825.
46. Halloran BP, Bikle DD, Cone CM, et al. Glucocorticoids and inhibition of bone formation induced by skeletal unloading. Am J Physiol. 1988;255:E875-E879.
47. Hanauer SB, Sandborn W. Management of CD in adults. Am J Gastroenterol. 2001;96:635-643.
48. D'Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in CD. Aliment Pharmacol Ther. 1998;12:419-424.
49. Wisniewski AF, Lewis SA, Green DJ, et al. Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma. Thorax. 1997;52:853-860.
50. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 1994;20:629-650.
51. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med. 1990;150:2545-2548.
52. Nielsen HK, Charles P, Mosekilde L. The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab. 1988;67:1025-1030.
53. Puolijoki H, Liippo K, Herrala J, et al. Inhaled beclomethasone decreases serum osteocalcin in postmenopausal asthmatic women. Bone. 1992;13:285-288.
54. Schulte C, Dignass AU, Mann K, et al. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol. 1999;34:696-702.
55. Nielsen HK, Eriksen EF, Storm T, et al. The effects of short-term, high-dose treatment with prednisone on the nuclear uptake of 1,25-dihydroxyvitamin D3 in monocytes from normal human subjects. Metabolism. 1988;37:109-114.
56. Angeli A, Dovio A, Sartori ML, et al. Interactions between glucocorticoids and cytokines in the bone microenvironment. Ann N Y Acad Sci. 2002;966:97-107.
57. Dovio A, Sartori ML, Masera RG, et al. Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. J Endocrinol. 2003;177:109-117.
58. Frost HM. On our age-related bone loss: insights from a new paradigm. J Bone Miner Res. 1997;12:1539-1546.
59. Frost HM. Muscle, bone, and the Utah paradigm: a 1999 overview. Med Sci Sports Exerc. 2000;32:911-917.
60. Lohman T. Exercise Training and Bone Mineral Density. Quest. 1995;47:354-361.
61. Activity and Health Research. Allied Dunbar national fitness survey: A report on activity patterns and fitness levels. 1992, Sports Council and Health Education Authority: London.
62. Silvennoinen J, Lamberg-Allardt C, Karkkainen M, et al. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med. 1996;240:285-292.
63. Pearson M, Teahon K, Levi AJ, et al. Food intolerance and CD. Gut. 1993;34:783-787.
64. Mishkin B, Yalovsky M, Mishkin S. Increased prevalence of lactose malabsorption in CD patients at low risk for lactose malabsorption based on ethnic origin. Am J Gastroenterol. 1997;92:1148-1153.
65. Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther. 1996;10:777-786.
66. Andreassen H, Rix M, Brot C, et al. Regulators of calcium homeostasis and bone mineral density in patients with CD. Scand J Gastroenterol. 1998;33:1087-1093.
67. Walters JR. The role of the intestine in bone homeostasis. Eur J Gastroenterol Hepatol. 2003;15:845-849.
68. Vogelsang H, Ferenci P, Resch H, et al. Prevention of bone mineral loss in patients with CD by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol. 1995;7:609-614.
69. Abitbol V, Mary JY, Roux C, et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther. 2002;16:919-927.
70. von Tirpitz C, Reinshagen M. Management of osteoporosis in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol. 2003;15:869-876.
71. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133:795-799.
72. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's Disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51-60.
73. Bemben DA, Fetters NL, Bemben MG, et al. Musculoskeletal responses to high- and low-intensity resistance training in early postmenopausal women. Med Sci Sports Exerc. 2000;32:1949-1957.
74. Chilibeck PD, Sale DG, Webber CE. Exercise and bone mineral density. Sports Med. 1995;19:103-122.
75. Ernst E. Exercise for female osteoporosis. A systematic review of randomised clinical trials. Sports Med. 1998;25:359-368.
76. Heinonen A, Kannus P, Sievanen H, et al. Randomised controlled trial of effect of high-impact exercise on selected risk factors for osteoporotic fractures. Lancet. 1996;348:1343-1347.
77. Humpheries. Effect of exercise intensity on bone density, strength, and calcium turnover in older women. Med Sci Sports Exerc. 2000;32:1043-1050.
78. Kerr D, Morton A, Dick I, et al. Exercise effects on bone mass in postmenopausal women are site-specific and load-dependent. J Bone Miner Res. 1996;11:218-225.
79. Burr DB. Muscle strength, bone mass, and age-related bone loss. J Bone Miner Res. 1997;12:1547-1551.
80. Taaffe DR, Cauley JA, Danielson M, et al. Race and sex effects on the association between muscle strength, soft tissue, and bone mineral density in healthy elders: the Health, Aging, and Body Composition Study. J Bone Miner Res. 2001;16:1343-1352.
81. Rittweger J, Beller G, Ehrig J, et al. Bone-muscle strength indices for the human lower leg. Bone. 2000;27:319-326.
82. Nordstrom P, Nordstrom G, Thorsen K, et al. Local bone mineral density, muscle strength, and exercise in adolescent boys: a comparative study of two groups with different muscle strength and exercise levels. Calcif Tissue Int. 1996;58:402-408.
83. Pettersson U, Nordstrom P, Lorentzon R. A comparison of bone mineral density and muscle strength in young male adults with different exercise level. Calcif Tissue Int. 1999;64:490-498.
84. Morey-Holton ER, Globus RK. Hindlimb unloading of growing rats: a model for predicting skeletal changes during space flight. Bone. 1998;22(5 Suppl):83S-88S.
85. Peterson SE, Peterson MD, Raymond G, et al. Muscular strength and bone density with weight training in middle-aged women. Med Sci Sports Exerc. 1991;23:499-504.
86. Nichols DL, Sanborn CF, Bonnick SL, et al. Relationship of regional body composition to bone mineral density in college females. Med Sci Sports Exerc. 1995;27:178-182.
87. Proctor KL, Adams WC, Shaffrath JD, et al. Upper-limb bone mineral density of female collegiate gymnasts versus controls. Med Sci Sports Exerc. 2002;34:1830-1835.
88. Conroy BP, Kraemer WJ, Maresh CM, et al. Bone mineral density in elite junior Olympic weightlifters. Med Sci Sports Exerc. 1993;25:1103-1109.
89. Haapasalo H, Kontulainen S, Sievanen H, et al. Exercise-induced bone gain is due to enlargement in bone size without a change in volumetric bone density: a peripheral quantitative computed tomography study of the upper arms of male tennis players. Bone. 2000;27:351-357.
90. Stewart AD, Hannan J. Total and regional bone density in male runners, cyclists, and controls. Med Sci Sports Exerc. 2000;32:1373-1377.
91. Taaffe DR, Marcus R. Regional and total body bone mineral density in elite collegiate male swimmers. J Sports Med Phys Fitness. 1999;39:154-159.
92. Leblanc AD, Schneider VS, Evans HJ, et al. Bone mineral loss and recovery after 17 weeks of bed rest. J Bone Miner Res. 1990;5:843-850.
93. Lohman T, Going S, Pamenter R, et al. Effects of resistance training on regional and total bone mineral density in premenopausal women: a randomized prospective study. J Bone Miner Res. 1995;10:1015-1024.
94. Robinson RJ, Krzywicki T, Almond L, et al. Effect of a low-impact exercise program on bone mineral density in CD: a randomized controlled trial. Gastroenterology. 1998;115:36-41.